Concentra Group Holdings Parent, Inc. (CON) Stock Analysis and Metrics

Concentra Group Holdings Parent

NYSE: CON

$31.61 ▼ -0.03 (-0.09%)

At close: Jul 17, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap39.41 Mn

P/E0.21

P/S0.02

Div. Yield0.81

ROIC (Qtr)0.00

Total Debt (Qtr)1.58 Bn

Revenue Growth (1y) (Qtr)13.74

Add ratio to table…

About

Concentra Group Holdings Parent, Inc. is the largest provider of occupational health services in the United States by number of locations. The company operates a nationwide network of occupational health centers, onsite health clinics, and a telemedicine platform designed to improve the health of America’s workforce. As of December 31, 2025, it maintained 628 stand alone occupational health centers across 41 states and 411 onsite health clinics at employer worksites in 44 states. Its telemedicine service reached 43 states and the District of Columbia, giving the company a presence in 47 states and the District of Columbia. The workforce included approximately 13,000 colleagues and affiliated physicians and clinicians who supported an average of about 53,000 patient visits each business day during 2025.

Revenue is generated primarily from workers’ compensation injury care and employer services such as physical examinations, drug and alcohol screenings, vaccinations, and consultative visits delivered at occupational health centers and onsite clinics. In addition, the company offers consumer health services for minor illnesses and injuries at its centers. For the year ended December 31, 2025, total revenue was $2,163.4 million, with approximately 93% derived from the occupational health centers segment, about 5% from onsite health clinics, and roughly 2% from other businesses. Customers include employers across the United States, workers’ compensation insurance carriers, third party administrators, and individuals seeking care at the facilities.

The company operates through the following segments: occupational health centers, onsite health clinics, and other businesses.

• Occupational health centers: This segment delivers workers’ compensation care and employer services including physical examinations, drug and alcohol screenings, vaccinations, and consultative visits at 628 stand alone occupational health centers located in 41 states.

• Onsite health clinics: This segment provides occupational health and employer sponsored primary care services at employer worksites, operating 411 clinics in 44 states and offering injury care, primary care, urgent care, preventive care, physical therapy, athletic training, and episodic specialty testing.

• Other businesses: This segment includes Concentra Telemed for remote treatment of work related injuries, Concentra Pharmacy for medication distribution, and Concentra Medical Compliance Administration for substance abuse program management, serving employers across the United States.

Concentra holds a leading position in the fragmented occupational health services industry as the largest provider by number of locations. Competitors range from independent single site practices and regional operator groups to hospital owned clinics and national urgent care chains that offer occupational health as an ancillary service. The company’s competitive advantages stem from its extensive geographic footprint, integrated service delivery across centers, clinics and telemedicine, long standing relationships with a broad base of employers including 100% of the Fortune 100, and investments in technology such as the Concentra HUB platform that streamline customer interactions and improve operational efficiency.

The company’s primary customers are employers across the United States, including 100% of the Fortune 100 companies, which together represent a significant portion of its revenue. In addition, Concentra works with numerous workers’ compensation insurance carriers and third party administrators such as Sedgwick, Gallagher Bassett, Travelers, Liberty Mutual, Chubb, eScreen, First Advantage, DISA, and Comprehensive Health Services. Patients receiving care are employees of these employer clients, contributing to an average of about 53,000 visits per business day.

Investment Thesis

▲ Bull case

Concentra Group Holdings Parent, Inc. is positioned to capitalize on the growing integration between occupational health and advanced primary care through its on-site clinics segment, which reported a 125% year-over-year revenue increase in Q1 2026 driven by the Pivot acquisition and strong organic growth. Excluding Pivot, the on-site health clinics segment still grew 20.9% year-over-year, indicating robust underlying demand. The company is leveraging its Epic EMR implementation across on-site locations to offer advanced primary care services—a white space it previously did not serve—thereby expanding its wallet share with existing employer customers. This strategic shift allows Concentra to move beyond traditional occupational medicine into higher-margin, recurring revenue models tied to employer-paid advanced primary care, with a serviceable addressable market estimated between $15 billion and $20 billion. The company’s nationwide footprint and employer relationships provide a significant competitive advantage over pure-play primary care providers, enabling rapid cross-selling and site expansion within current client bases. Management’s focus on advanced primary care as a key growth lever, combined with a robust pipeline of opportunities across both occupational medicine and advanced primary care, suggests that this segment could become a material contributor to long-term margin expansion and revenue diversification, especially as employer demand for preventive and holistic health solutions continues to rise.
The company’s de novo center expansion strategy is progressing ahead of expectations, with plans to open eight to ten new centers in 2026 across high-growth markets including Arizona, Idaho, Missouri, Illinois, Virginia, South Carolina, and Florida. This organic growth initiative, separate from bolt-on acquisitions, represents a low-capital-intensity, high-return avenue for revenue expansion, particularly in underserved or emerging industrial corridors. The de novo rollout is being strategically aligned with macroeconomic trends such as infrastructure build-out, onshoring momentum in manufacturing and construction, and AI-driven facility expansion—factors that directly increase demand for occupational health services. Notably, Concentra highlighted that construction industry growth, fueled by AI infrastructure investments, is becoming a meaningful tailwind for its employer services and workers’ compensation segments. By targeting geographies where new industrial and logistics hubs are developing, the company is positioning itself to capture early-mover advantage in high-traffic employer zones. The success of prior de novos, combined with a disciplined site selection process based on economic activity tracking, reduces execution risk and enhances the predictability of this growth channel. As these centers mature, they will contribute to same-store sales growth and improve overall network density, strengthening Concentra’s competitive moat in local markets.
Concentra’s free cash flow generation is showing signs of acceleration, with Q1 2026 free cash flow rising to $9.9 million from negative $4 million in the prior year period, driven by higher earnings and lower capital spending. The company raised its full-year 2026 free cash flow guidance range to $215 million to $235 million, reflecting confidence in sustained earnings improvement and disciplined capital allocation. This strong free cash flow conversion supports ongoing deleveraging, with the net leverage ratio already down to 3.4 times as of March 2026 and expected to fall comfortably below 3.0 times by year-end. Lower leverage reduces financial risk and increases flexibility for future capital deployment, whether through additional bolt-on acquisitions, dividend increases, or share repurchases. The company ended Q1 with $65 million remaining under its share repurchase authorization, signaling continued commitment to returning capital to shareholders. Furthermore, the separation from Select is progressing ahead of schedule, with over 95% of expected new FTEs hired and key back-office technology milestones on track for completion by summer 2026—well before the November 2026 deadline. This operational independence eliminates a potential overhang and allows Concentra to fully realize the benefits of its standalone cost structure and agility in decision-making. The combination of improving profitability, declining leverage, and operational readiness for independent execution creates a favorable environment for multiple expansion and sustained shareholder value creation.

Concentra Group Holdings Parent, Inc. is positioned to capitalize on the growing integration between occupational health and advanced primary care through its on-site clinics segment, which reported a 125% year-over-year revenue increase in Q1 2026 driven by the Pivot acquisition and strong organic growth. Excluding Pivot, the on-site health clinics segment still grew 20.9% year-over-year, indicating robust underlying demand. The company is leveraging its Epic EMR implementation across on-site locations to offer advanced primary care services—a white space it previously did not serve—thereby expanding its wallet share with existing employer customers. This strategic shift allows Concentra to move beyond traditional occupational medicine into higher-margin, recurring revenue models tied to employer-paid advanced primary care, with a serviceable addressable market estimated between $15 billion and $20 billion. The company’s nationwide footprint and employer relationships provide a significant competitive advantage over pure-play primary care providers, enabling rapid cross-selling and site expansion within current client bases. Management’s focus on advanced primary care as a key growth lever, combined with a robust pipeline of opportunities across both occupational medicine and advanced primary care, suggests that this segment could become a material contributor to long-term margin expansion and revenue diversification, especially as employer demand for preventive and holistic health solutions continues to rise.
The company’s de novo center expansion strategy is progressing ahead of expectations, with plans to open eight to ten new centers in 2026 across high-growth markets including Arizona, Idaho, Missouri, Illinois, Virginia, South Carolina, and Florida. This organic growth initiative, separate from bolt-on acquisitions, represents a low-capital-intensity, high-return avenue for revenue expansion, particularly in underserved or emerging industrial corridors. The de novo rollout is being strategically aligned with macroeconomic trends such as infrastructure build-out, onshoring momentum in manufacturing and construction, and AI-driven facility expansion—factors that directly increase demand for occupational health services. Notably, Concentra highlighted that construction industry growth, fueled by AI infrastructure investments, is becoming a meaningful tailwind for its employer services and workers’ compensation segments. By targeting geographies where new industrial and logistics hubs are developing, the company is positioning itself to capture early-mover advantage in high-traffic employer zones. The success of prior de novos, combined with a disciplined site selection process based on economic activity tracking, reduces execution risk and enhances the predictability of this growth channel. As these centers mature, they will contribute to same-store sales growth and improve overall network density, strengthening Concentra’s competitive moat in local markets.
Concentra’s free cash flow generation is showing signs of acceleration, with Q1 2026 free cash flow rising to $9.9 million from negative $4 million in the prior year period, driven by higher earnings and lower capital spending. The company raised its full-year 2026 free cash flow guidance range to $215 million to $235 million, reflecting confidence in sustained earnings improvement and disciplined capital allocation. This strong free cash flow conversion supports ongoing deleveraging, with the net leverage ratio already down to 3.4 times as of March 2026 and expected to fall comfortably below 3.0 times by year-end. Lower leverage reduces financial risk and increases flexibility for future capital deployment, whether through additional bolt-on acquisitions, dividend increases, or share repurchases. The company ended Q1 with $65 million remaining under its share repurchase authorization, signaling continued commitment to returning capital to shareholders. Furthermore, the separation from Select is progressing ahead of schedule, with over 95% of expected new FTEs hired and key back-office technology milestones on track for completion by summer 2026—well before the November 2026 deadline. This operational independence eliminates a potential overhang and allows Concentra to fully realize the benefits of its standalone cost structure and agility in decision-making. The combination of improving profitability, declining leverage, and operational readiness for independent execution creates a favorable environment for multiple expansion and sustained shareholder value creation.

▼ Bear case

Concentra Group Holdings Parent, Inc.’s employer services segment continues to show muted growth, with visits per day increasing only 0.7% year-over-year when excluding the Nova acquisition, signaling persistent weakness in hiring and workforce turnover trends among its core employer base. Despite management’s optimism about accelerating job growth, the lack of meaningful improvement in employer services visit volume—particularly in contrast to the 6.2% growth in workers’ compensation visits—suggests that the company may be over-relying on injury-driven demand rather than proactive workforce health engagement. Employer services, which serve as an entry point for broader occupational health relationships, remain a lower-margin offering, and its stagnation limits opportunities for cross-selling into higher-value services like on-site advanced primary care. The company’s reliance on workers’ compensation as the primary revenue engine (approximately two-thirds of center revenue) makes it vulnerable to fluctuations in workplace injury rates, which are influenced by external factors such as seasonality, economic shifts, and regulatory changes. While management cited winter weather as a net positive in Q1 2026 due to increased slips and falls, this highlights the segment’s sensitivity to unpredictable environmental conditions rather than durable, structural demand. The inability to meaningfully grow employer services organically raises concerns about the sustainability of customer acquisition and long-term relationship depth, especially in a macroeconomic environment where hiring remains subdued.
Although Concentra raised its full-year 2026 guidance, the upward revision was modest—increasing revenue guidance by only $25 million to a range of $2.275 billion to $2.375 billion and adjusted EBITDA by $10 million to $460 million to $480 million—suggesting limited confidence in a significant inflection point in performance. The company’s organic revenue growth, excluding acquisitions, was just 6.3% in Q1 2026, indicating that the top-line expansion is heavily dependent on integration benefits from prior deals like Nova and Pivot rather than organic momentum. Furthermore, the workers’ compensation revenue per visit growth of only 2% in Q1 2026 (1.3% excluding Nova) fell short of historical averages and was partially attributed to unfavorable visit mix, raising questions about the durability of pricing power. Management acknowledged that without the favorable shift in visit mix, the underlying rate increase would have been only 2.3% to 2.4%, implying that the reported growth may not reflect true fee schedule or pricing improvements. The company’s dependence on state-level workers’ compensation fee schedule updates—only about 75% to 80% of which typically occur in Q1—means that future rate benefits will be incremental and unevenly distributed across quarters, making consistent revenue per visit growth difficult to achieve. This reliance on periodic, geographically scattered rate adjustments introduces volatility and limits predictability in the core pricing driver of the business.
Concentra’s on-site health clinics segment, while highlighted as a growth opportunity, remains heavily dependent on the Pivot acquisition for its reported performance, with organic growth of 20.9% year-over-year in Q1 2026 coming off a relatively low base of $64 million in 2024 revenue. Despite management’s enthusiasm about the $15 billion to $20 billion serviceable addressable market, the current run-rate of approaching $150 million in revenue indicates that penetration remains below 1%, suggesting significant challenges in scaling beyond early adopters. The expansion into advanced primary care requires not only technological integration (such as Epic EMR) but also shifts in employer buying behavior, broker influence, and care delivery models—factors that may evolve more slowly than anticipated. Additionally, the segment’s growth is tied to the success of cross-selling within the existing employer base, which presupposes strong relationships and trust that may not translate uniformly across all client segments, particularly those focused solely on cost containment in traditional occupational health. The company’s ability to replicate Pivot’s success through organic growth or smaller bolt-ons remains unproven, and the sales cycle for enterprise-wide on-site advanced primary care deployments is likely longer and more complex than implied by management’s optimistic commentary. Without clear metrics on customer acquisition costs, retention rates, or margin progression in this segment, the long-term profitability and scalability of the on-site advanced primary care initiative remain uncertain.

Concentra Group Holdings Parent, Inc.’s employer services segment continues to show muted growth, with visits per day increasing only 0.7% year-over-year when excluding the Nova acquisition, signaling persistent weakness in hiring and workforce turnover trends among its core employer base. Despite management’s optimism about accelerating job growth, the lack of meaningful improvement in employer services visit volume—particularly in contrast to the 6.2% growth in workers’ compensation visits—suggests that the company may be over-relying on injury-driven demand rather than proactive workforce health engagement. Employer services, which serve as an entry point for broader occupational health relationships, remain a lower-margin offering, and its stagnation limits opportunities for cross-selling into higher-value services like on-site advanced primary care. The company’s reliance on workers’ compensation as the primary revenue engine (approximately two-thirds of center revenue) makes it vulnerable to fluctuations in workplace injury rates, which are influenced by external factors such as seasonality, economic shifts, and regulatory changes. While management cited winter weather as a net positive in Q1 2026 due to increased slips and falls, this highlights the segment’s sensitivity to unpredictable environmental conditions rather than durable, structural demand. The inability to meaningfully grow employer services organically raises concerns about the sustainability of customer acquisition and long-term relationship depth, especially in a macroeconomic environment where hiring remains subdued.
Although Concentra raised its full-year 2026 guidance, the upward revision was modest—increasing revenue guidance by only $25 million to a range of $2.275 billion to $2.375 billion and adjusted EBITDA by $10 million to $460 million to $480 million—suggesting limited confidence in a significant inflection point in performance. The company’s organic revenue growth, excluding acquisitions, was just 6.3% in Q1 2026, indicating that the top-line expansion is heavily dependent on integration benefits from prior deals like Nova and Pivot rather than organic momentum. Furthermore, the workers’ compensation revenue per visit growth of only 2% in Q1 2026 (1.3% excluding Nova) fell short of historical averages and was partially attributed to unfavorable visit mix, raising questions about the durability of pricing power. Management acknowledged that without the favorable shift in visit mix, the underlying rate increase would have been only 2.3% to 2.4%, implying that the reported growth may not reflect true fee schedule or pricing improvements. The company’s dependence on state-level workers’ compensation fee schedule updates—only about 75% to 80% of which typically occur in Q1—means that future rate benefits will be incremental and unevenly distributed across quarters, making consistent revenue per visit growth difficult to achieve. This reliance on periodic, geographically scattered rate adjustments introduces volatility and limits predictability in the core pricing driver of the business.
Concentra’s on-site health clinics segment, while highlighted as a growth opportunity, remains heavily dependent on the Pivot acquisition for its reported performance, with organic growth of 20.9% year-over-year in Q1 2026 coming off a relatively low base of $64 million in 2024 revenue. Despite management’s enthusiasm about the $15 billion to $20 billion serviceable addressable market, the current run-rate of approaching $150 million in revenue indicates that penetration remains below 1%, suggesting significant challenges in scaling beyond early adopters. The expansion into advanced primary care requires not only technological integration (such as Epic EMR) but also shifts in employer buying behavior, broker influence, and care delivery models—factors that may evolve more slowly than anticipated. Additionally, the segment’s growth is tied to the success of cross-selling within the existing employer base, which presupposes strong relationships and trust that may not translate uniformly across all client segments, particularly those focused solely on cost containment in traditional occupational health. The company’s ability to replicate Pivot’s success through organic growth or smaller bolt-ons remains unproven, and the sales cycle for enterprise-wide on-site advanced primary care deployments is likely longer and more complex than implied by management’s optimistic commentary. Without clear metrics on customer acquisition costs, retention rates, or margin progression in this segment, the long-term profitability and scalability of the on-site advanced primary care initiative remain uncertain.

Peer Comparison

Companies in the Medical Care Facilities

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	HCA	HCA Healthcare, Inc.	87.94 Bn	11.25	1.15	48.02 Bn
2	CHE	Chemed Corp	18.08 Bn	51.68	7.12	0.09 Bn
3	THC	Tenet Healthcare Corp	16.59 Bn	9.74	0.77	13.21 Bn
4	DVA	Davita Inc.	15.37 Bn	14.02	1.10	10.63 Bn
5	EHC	Encompass Health Corp	10.07 Bn	654.20	1.66	2.57 Bn
6	ENSG	Ensign Group, Inc	9.52 Bn	27.18	1.81	0.14 Bn
7	UHS	Universal Health Services Inc	9.19 Bn	6.05	0.52	4.71 Bn
8	PACS	PACS Group, Inc.	6.96 Bn	28.55	1.28	0.05 Bn

Research Tools

Developers

About

Investment Thesis

Segments Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Segments Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password